"GI ASCO Updates: Challenging Chemotherapy with Biomarker Breakthrough" and “ASCO Updates – Rad Oncology”

Objectives (a couple more to come)

Objectives:

  1. Define actionable alterations in second Line biliary tract cancer
  2. Summarize the role of KRAS in HER2 targeting strategies
  3. Discuss the results of improved overall survival demonstrated on the PREOPANC study with the use of neoadjuvant chemotherapy versus chemoradiation therapy.
  4. Discuss the use of 177Lu-PSMA-617 in the treatment of metastatic castrate resistant prostate cancer

***This session will VIRTUAL via zoom***

Zoom information:

Join from a PC, Mac, iPad, iPhone or Android device:

    Please click this URL to join. https://uwmadison.zoom.us/s/97907845208?pwd=c0lldVdDa1pEUUpmdEZ1SXlpL05Ydz09

    Passcode: UWCCC

Or One tap mobile:

    +13126266799,,97907845208# US (Chicago)

    +19292056099,,97907845208# US (New York)

Or join by phone:

    Dial(for higher quality, dial a number based on your current location):

        US: +1 312 626 6799  or +1 929 205 6099  or +1 301 715 8592  or +1 346 248 7799  or +1 669 900 6833  or +1 253 215 8782

    Webinar ID: 979 0784 5208

    International numbers available: https://uwmadison.zoom.us/u/abwFikBNtn

 

Session date: 
Wednesday, September 1, 2021 - 8:00am to 9:00am
Location: 
HSLC Lecture Hall #1306
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Dr. Adam Burr
Dr. Jeremy Kratz